TrialFuture oncology (London, England)2026

Precision palliative care in advanced/recurrent esophageal cancer patients treated with anti-PD-1/PD-L1 immunotherapy (ESO-Shanghai 25): a randomized, phase III Trial.

Shengnan Hao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.